Advice
in the absence of a submission from the holder of the marketing authorisation:
eribulin (Halaven®) is not recommended for use within NHSScotland.
Indication under review: Treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice354KB (PDF)
Medicine details
- Medicine name:
- eribulin (Halaven)
- SMC ID:
- SMC2231
- Indication:
Treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.
- Pharmaceutical company
- Eisai Ltd
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 September 2019